IRNF App vs LINQ II Insertable Cardiac Monitor

Similar category, different focus. These tools serve overlapping but distinct needs. Comparability 60/100 Comparability is an AI-graded 0–100 score of how directly these two tools compete — higher means a more apples-to-apples comparison.

IRNF App

by Apple

LINQ II Insertable Cardiac Monitor

by Medtronic

AI Verdict

While both tools leverage AI for heart rhythm analysis and are FDA-cleared, they serve distinct purposes and target different user groups. The IRNF App is a non-invasive, consumer-facing screening tool for irregular rhythms using a wearable device, whereas the LINQ II is an invasive, long-term insertable cardiac monitor designed for comprehensive clinical diagnosis and monitoring of various arrhythmias. Their differing deployment methods and clinical applications make them suitable for adjacent, rather than directly competing, use cases in cardiac care.

Choose IRNF App if…

Choose the IRNF App if you are an individual seeking a convenient, non-invasive, and cost-free method for proactive monitoring of irregular heart rhythms suggestive of AFib. This tool is ideal for general wellness awareness or as an initial screening step, leveraging your existing Apple Watch and iPhone for over-the-counter use.

View IRNF App →

Choose LINQ II Insertable Cardiac Monitor if…

Choose the LINQ II Insertable Cardiac Monitor if you require definitive, long-term, and highly accurate continuous monitoring for infrequent or elusive arrhythmias. This device is best suited for patients where physician-managed, comprehensive data over an extended period (up to 4.5 years) is critical for diagnosis, treatment planning, and ongoing management, especially when non-invasive methods have been insufficient.

View LINQ II Insertable Cardiac Monitor →

Reviewed by Pouyan Golshani, MD — Interventional Radiologist

Quick Comparison

Feature	IRNF App	LINQ II Insertable Cardiac Monitor
Deployment	Unknown	Subcutaneous implant with remote monitoring via mobile app or home communicator.
FDA Status	Unknown	Cleared AI-estimated

Head-to-Head

AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.

Usability

IRNF App

Tool A, the IRNF App, is a software-only mobile application integrated into familiar Apple devices, offering a highly intuitive and non-invasive user experience for the general public. Its design prioritizes ease of use and accessibility for individual consumers. Tool B, while having a mobile app, requires an invasive surgical procedure for device implantation, making its overall 'usability' for the patient significantly more involved.

Clinical Value

LINQ II Insertable Cardiac Monitor

Tool B, the LINQ II, provides long-term, continuous heart rhythm monitoring with advanced AI algorithms for diagnosing a broader range of arrhythmias, including a pediatric indication, offering comprehensive diagnostic data for clinicians. Tool A, while FDA-cleared, primarily serves as a screening tool to detect irregular rhythms suggestive of AFib, focusing on user notification rather than definitive diagnosis or long-term, continuous clinical-grade monitoring across various arrhythmias.

Pricing & Value

IRNF App

Tool A offers exceptional value as it is a free feature included with compatible Apple Watch and iPhone models, providing a valuable health screening tool at no additional cost to the user. Tool B is an enterprise-priced medical device requiring surgical implantation, with costs typically negotiated with healthcare systems, representing a significant investment for both providers and potentially patients.

Enterprise Readiness

LINQ II Insertable Cardiac Monitor

Tool B is explicitly designed for healthcare systems, featuring HIPAA compliance, remote programming capabilities, and a track record of deployment in solo to large health systems. Tool A, lacking a Business Associate Agreement (BAA) and being a consumer-facing application, is not structured for direct integration or management within enterprise healthcare environments.

Innovation

IRNF App

Tool A represents a significant innovation by democratizing FDA-cleared, medical-grade irregular rhythm detection through a software-only application on a widely adopted consumer wearable. This made advanced cardiac screening accessible to millions. While Tool B offers advanced AI and remote capabilities within an implantable device, Tool A's innovation lies in its broad public health impact and accessibility of a medical AI feature.

Support & Docs

Tie

Both Apple and Medtronic are global leaders known for robust customer and professional support, respectively. Tool A benefits from Apple's extensive consumer support ecosystem and user-friendly educational materials. Tool B, as a medical device, would have comprehensive professional support for clinicians and patient support programs. Without specific comparative details on the quality or breadth of documentation and support for these particular offerings, it is difficult to definitively choose a winner.

Feature-by-Feature

Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.

Feature	IRNF App	LINQ II Insertable Cardiac Monitor
Product Name	IRNF App	LINQ II Insertable Cardiac Monitor
Company	Apple	Medtronic
Primary Monitoring Technology	Wearable (Apple Watch PPG sensor)	Insertable Cardiac Monitor
AI/Machine Learning Use	Utilizes machine learning for rhythm classification	AccuRhythmu2122 AI algorithms for enhanced accuracy
Data Management App	Apple Health app	MyCareLink Heartu2122 mobile app
Maximum Continuous Monitoring Duration	Not specified	Up to 4.5 years

Videos

Demos, reviews, and walkthroughs featuring IRNF App and LINQ II Insertable Cardiac Monitor.

Loading videos…

Videos need JavaScript to load. Search YouTube directly →

View all on YouTube

Frequently Asked Questions

How do these tools differ in their clinical utility and workflow integration for diagnosing or monitoring arrhythmias?

The IRNF App functions as an over-the-counter screening tool for irregular rhythms suggestive of AFib, relying on patient-initiated use and notifications via the Apple Health app. In contrast, the LINQ II is a physician-prescribed insertable cardiac monitor that provides continuous, long-term, high-fidelity ECG data for diagnosing a range of arrhythmias, integrating into a clinical remote monitoring workflow.

What is the comparative accuracy and sensitivity of each tool for detecting and diagnosing specific cardiac arrhythmias?

The IRNF App detects 'irregular heart rhythms suggestive of Atrial Fibrillation (AFib)' using PPG sensor data and machine learning, with a reported person-level sensitivity of 88.6% and specificity of 99.3% for AFib. The LINQ II, an insertable device, offers 'enhanced accuracy for diagnosing arrhythmias' with 'AccuRhythmu2122 AI algorithms' that reduce false alerts while preserving true AF alerts, and includes an 'innovative PVC detection algorithm' for definitive diagnosis.

What are the mechanisms for integrating data from each device into a patient's electronic health record (EHR)?

The IRNF App integrates with the Apple Health app for data storage and management, meaning physicians would typically rely on patient-reported notifications or manual data review from Apple Health. The LINQ II utilizes the MyCareLink Heartu2122 mobile app or MyCareLink Relayu2122 home communicator for data transmission to the CareLinku2122 network, suggesting a more structured and potentially automated data flow for clinical systems.

For which specific patient populations or clinical scenarios is each tool most appropriately indicated?

The IRNF App is intended for over-the-counter use by individuals aged 22 and over who are interested in screening for irregular rhythms suggestive of AFib and have no previous AFib diagnosis. The LINQ II is indicated for adult and pediatric patients (ages 2+) with clinical syndromes or transient symptoms suggesting cardiac arrhythmias, requiring long-term, continuous monitoring for diagnosis.

What level of physician and staff training or support is provided for effectively utilizing each tool and interpreting its data?

The IRNF App provides 'onboarding and educational materials for users' (patients), implying a self-service model for patients and indirect physician support for interpreting patient-reported data. Medtronic offers extensive clinician education and training resources for the LINQ II, including learning plans for insertion workflow and managing patients on the CareLinku2122 Network, indicating professional support for healthcare providers.

How do the long-term monitoring capabilities and time-to-value differ between these two devices?

The IRNF App provides opportunistic monitoring when the Apple Watch is worn and the user is still, offering notifications and a history of AFib notifications. The LINQ II offers significantly longer 'up to 4.5 years of continuous monitoring,' providing extended diagnostic periods and sustained remote management for long-term arrhythmia detection and management, potentially reducing clinic review burden.

What additional security measures are in place to protect patient data, beyond basic compliance, given their different data collection and transmission methods?

The IRNF App saves all collected data to the Apple Health app on the iPhone, relying on the security framework of the Apple ecosystem, with users controlling data sharing. The LINQ II system utilizes end-to-end encryption to keep LINQ II data secure during transmission via the MyCareLink Heartu2122 mobile app or MyCareLink Relayu2122 home communicator to the clinic.

More Comparisons

Assert-IQ vs Rapid Enterprise Platform

AISAP Cardio vs Rapid Enterprise Platform

AngioWaveNet vs Rapid Enterprise Platform

CorVista System with PH Add-On vs Rapid Enterprise Platform

More matchups featuring IRNF App or LINQ II Insertable Cardiac Monitor

Backers

Who funded each tool's parent company.

IRNF App

Transformer VC